Lung cancer and oncolytic virotherapy—enemy’s enemy

Zhang Li a, Zhang Feiyue b, Li Gaofeng c, Liang Haifeng a,*,

a Department of Oncology, Gejiu People’s Hospital, The Fifth Affiliated Hospital of Kunming Medical University, China
b Department of Oncology, Yuxi People’s Hospital, The Sixth Affiliated Hospital of Kunming Medical University, China
c Department of Thoracic Surgery, Yunnan Cancer Center, The Third Affiliated Hospital of Kunming Medical University, China

ARTICLE INFO

Keywords:
Lung cancer
Oncolytic virotherapy
Immunotherapy
Virus design
Combination therapy

ABSTRACT

Lung cancer is one of the malignant tumors that seriously threaten human health worldwide, while the covid-19 virus has become people’s nightmare after the coronavirus pandemic. There are too many similarities between cancer cells and viruses, one of the most significant is that both of them are our enemies. The strategy to take the advantage of the virus to beat cancer cells is called Oncolytic virotherapy. When immunotherapy represented by immune checkpoint inhibitors has made remarkable breakthroughs in the clinical practice of lung cancer, the induction of antitumor immunity from immune cells gradually becomes a rapidly developing and promising strategy of cancer therapy. Oncolytic virotherapy is based on the same mechanisms that selectively kill tumor cells and induce systemic anti-tumor immunity, but still has a long way to go before it becomes a standard treatment for lung cancer. This article provides a comprehensive review of the latest progress in oncolytic virotherapy for lung cancer, including the specific mechanism of oncolytic virus therapy and the main types of oncolytic viruses, and the combination of oncolytic virotherapy and existing standard treatments. It aims to provide new insights and ideas on oncolytic virotherapy for lung cancer.

Introduction

Lung cancer is one of the malignant tumors with the highest morbidity and mortality, a small number of patients with advanced lung cancer have achieved unprecedented clinical effects from immunotherapy represented by immune checkpoint inhibitors (ICIs) [1]. Oncolytic virotherapy (OV) is another type of cancer immunotherapy with broad anticancer activity [2]. The concept of using the oncolytic virus to treat cancer has now been demonstrated in several recent clinical trials, and a real therapy for melanoma received FDA approval [3]. A systematic review and meta-analyses evaluate the efficacy and safety of OV in lung cancer and showed that the objective response rate was significantly higher in patients receiving oncolytic adenovirus H101 monotherapy or combination with chemotherapy than in patients only receiving chemotherapy [4]. OV has broad research prospects in the field of lung cancer.

How does OV work in lung cancer?

OV is increasingly important in cancer therapy because they combine direct oncolysis with stimulation of antitumor immunity (Fig. 1).

Oncolytic viruses are designed to preferentially infect and replicate in tumors, which not only promotes immunogenic cell death but also increases the number of immune mediators entering the tumor microenvironment that disrupt intratumoral immunosuppression and induce systemic antitumor immunity of the host [5,6]. Enadenotucirev (previously known as ColoAd1), a tumor-selective chimeric adenovirus, was detected in resectable non-small cell lung cancer (NSCLC) to stimulate local high antitumor immune response such as the infiltration of CD8+ T cell [7]. Furthermore, using oncolytic adenovirus or vaccinia virus-infected reprogrammed somatic-derived tumor cell vaccine (VIR-eST) regimen to vaccinate high-risk populations can prevent tumor progression and initiate long-term anti-tumor immune response monitoring, which can be used in the treatment and prevention of lung cancer [8]. Besides, computers could identify optimal vaccine candidates for subunits of an oncogenic virus that causes lung cancer, and these epitopes have great therapeutic potential as vaccines against lung cancer [9]. More and more breakthroughs have been made in preclinical and clinical trials of OV for lung cancer, as shown in Tables 1 and 2.

* Corresponding author.
E-mail address: lh0671@126.com (L. Haifeng).

https://doi.org/10.1016/j.tranon.2022.101563
Received 24 August 2022; Received in revised form 27 September 2022; Accepted 10 October 2022
1936-5233/© 2022 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Design and delivery of oncolytic viruses

Tumor-associated stroma limits the efficacy of oncolytic viruses by forming barriers that prevent efficient virus penetration and spread, and more critically, their viral therapeutic efficacy is strongly hindered by limited viral spread and negative immune regulation in the tumor microenvironment [27]. One of the limitations of intravascular delivery of oncolytic viruses is that systemic administration will be hindered by antiviral immunity. Some studies have obtained adenoviral vector Ad5-3M by targeting functional sites in the viral capsid. Delivering oncolytic virus to mice with lung cancer not only observed that the virus replicated in tumor cells inhibited tumor growth, but also resisted antiviral immunity [28]. To enhance antitumor activity, Blood Outgrowth Endothelial Cells (BOEC) can be used to deliver the interferon-β-expressing oncolytic vesicular stomatitis virus VSV-IFNβ vector in a preclinical model of NSCLC, with VSV-IFNβ-infected human BOECs showed excellent antitumor activity and mouse survival in immunodeficient A549 xenograft model mice and infected BOECs killed NSCLC cells in vitro and protected VSV-IFNβ from antibodies [29]. Coincidentally, microfluidic encapsulation of oncolytic adenovirus demonstrated excellent in vivo antitumor activity against A549 lung tumor-bearing mice through a combination of inhibiting proliferation, and amplifying oncolysis, and potentially immunomodulating [30]. Additional studies have shown that systemic delivery of oncolytic adenovirus and paclitaxel encapsulated in extracellular vesicle (EV) preparations significantly increased transduction rates and infectious titers in vitro, while effectively inhibiting the growth of human lung cancer in animal xenograft models [31]. At the same time, the virus itself can also be used as a carrier for other treatments. The use of viral vectors and cationic carriers combined with various aerosol delivery technologies can develop new specific carriers for lung cancer treatment [32].

A second major limitation of the therapeutic efficacy of oncolytic viruses is antagonism by limited diffusion within solid tumors. AdUV was isolated by repeated treatment of viral particles of the oncolytic adenovirus wild-type Ad5 dl309 with C-type UV irradiation, which was shown to lyse cancer cells more efficiently [33]. Moreover, the function of oncolytic viruses is dependent on the immune response in the tumor microenvironment, and the combination therapy of interleukin 10 (IL-10) and oncolytic adenovirus Ad-hTERT in the treatment of lung cancer enhanced the antitumor efficacy [34]. Systemic administration of the IL-12-expressing NV1042 virus also performs more effectively in treating metastatic lung tumors than its non-cytokine parent, NV1023 [35]. The use of secreted or membrane-bound IL-23 vaccinia virus induces antitumor effects in a variety of tumor models [36].

Effective immunotherapy requires simultaneous targeting of cancer cells and immunosuppressive stromal cells, and poor tumor targeting of oncolytic adenoviruses after systemic administration is considered the third major limitation of viral therapy for disseminated cancer. To enhance the targeted ability of oncolytic viruses, some research finds that tumor-infiltrating T cells can be more efficiently activated and redirected by oncolytic adenoviruses equipped with bispecific T cell engager (BiTE) antibodies, and arming oncolytic adenoviruses with BiTEs could overcome “targeted limitation” of OV [37]. An engineered oncolytic group B adenovirus encoding with BiTEs could target both tumor cells and immunosuppressive stromal cells. This BiTE binds fibroblast activation protein (FAP) on cancer-associated fibroblasts (CAFs) and CD3ε on T cells, resulting in efficient T cell activation and fibroblast death [38]. As FAP is highly overexpressed in CAFs, oncolytic adenovirus OAd-FBiTE armed with FAP-targeting bispecific T cells can retarget infiltrating lymphocytes to CAFs, enhancing viral spread and T cell-mediated cytotoxicity targeting of tumor stroma [39]. Another oncolytic herpesvirus expressing PD-L1 BiTE, which produces a pro-inflammatory response and eliminates cells that promote tumor progression, also prevents systemic toxicity [40].

Oncolytic virus combined with standard treatment of lung cancer

In a meta-analysis of the efficacy and safety of oncolytic virus combination therapy, combination therapy improved objective response rates in lung cancer patients compared with conventional therapy alone [41]. OV is a particularly attractive option for preventing postoperative local recurrence and distant metastasis, and improving postoperative survival in lung cancer patients, they can directly target residual tumor deposits and beneficially modulate the postoperatively suppressed systemic immune environment [42]. Meanwhile, radiotherapy has shown excellent immunoediting activity in NSCLC, and combining OV with it provides an optimal strategy for lung cancer treatment [43].
combination of radiation therapy and the oncolytic virus can increase the antitumor effect and selectively kill human NSCLC cells [44].

Even more striking is that the combination of chemotherapeutic drugs and oncolytic viruses showed stronger cytotoxicity and oncolytic effects, as shown in Table 3.

**Oncolytic virus combined with lung cancer immunotherapy strategy**

By interfering with cancer-mediated immunosuppression, ICIs have been approved as a standard treatment for a variety of malignancies, including NSCLC [53]. However, most patients do not respond well to ICI-based immunotherapy, and OV is one of many promising immunomodulatory therapies that could improve the efficacy of the immune microenvironment by modifying the tumor, promoting T cell infiltration within the tumor, and can improve the response rate of ICIs, thereby improving anti-PD-1 immunotherapy [54,55]. Viruses are well-known immunosensitizers that cause tumor cell lysis and promote immune-mediated tumor cell recognition and destruction [56]. For example, the oncolytic adenovirus Delta-24-RGDOX expressing the immune co-stimulatory factor OX40 ligand (OX40L) combined with tumor-targeted ICIs exhibits excellent tumor-specific lymphocyte activation and tumor-associated antigen specificity proliferation of CD8+ T cells, thereby activating antitumor immunity [57]. Infection with low pathogenicity influenza virus (IAV) combined with ICI resulted in increased levels of M1-polarized alveolar macrophages and increased lung infiltration by cytotoxic T lymphocytes in NSCLC, suggesting that IAV has synergistic antitumor efficacy against ICI-resistant lung cancer and Immunomodulatory efficacy [58]. Another triple therapy combining oVV with PD-1 or TIM-3 blockade was proved to be more effective in refractory lung cancer [59]. Combining oncolytic viruses with tumor-targeted ICIs is a competitive strategy for the treatment of lung cancer.

**Another direction is to directly arm oncolytic viruses with ICIs**

A novel recombinant oncolytic virus virus, VV-α-TIGIT, encoding a fully monoclonal antibody against T cell immunoglobulin and ITIM domain (TIGIT) significantly increased T cell recruitment and activation in the tumor microenvironment [60]. Another engineered oncolytic vaccinia virus, VV-scFv-TIGIT, encoding a single-chain variable fragment (scFv) targeting T-cell immunoglobulin and ITIM domain, induces

### Table 3

| Oncolytic virus | Mechanism | Ref. |
|----------------|-----------|-----|
| Newcastle Disease Virus (NDV) | Selectively kills malignant cells | [10] |
| NDV | NDV is a potent inducer of immunogenic cell death (ICD). | [11] |
| rNDV-GFP | rNDV-GFP maintains tumor-selective replication properties and induces tumor cell apoptosis. | [12] |
| NDV-FMV | NDV-FMV triggers caspase-dependent apoptosis in lung cancer spheres and promotes autophagic degradation in lung cancer spheres by inhibiting the AKT/mTOR pathway | [13] |
| NDV-HIJ | Virus-selective oncolysis is dependent on apoptosis and is associated with higher levels of viral transcription, translation, and progeny virus formation. | [14] |
| Coxackievirus B3 (CVB3) | CVB3 is a potent oncolytic virus for KRAS-mutant lung adenocarcinoma-targeted therapy. | [15] |
| microRNA-modified CVB3 (mir-CVB3) | mir-CVB3 retains the ability to infect and lyse KRAS-mutant lung adenocarcinoma and TP53/RB1-mutant SCLC cells | [16], [17] |
| EHV-1 | Animal virus EHV-1 replicates efficiently in a human adenocarcinoma cell line (A549) | [18] |
| Oncopox-trail | The TRAIL protein mainly induces apoptosis and inhibits necrosis, and the oncolytic poxviruses carrying the trail gene have better cytotoxicity | [19] |
| CF33-GFP | Infiltration of tumors by CD8+ T cells | [20] |
| Bovine Herpesvirus 1 (BoHV-1) | BoHV-1 infection of tumors reduces their protein levels of histone deacetylase (HDAC) by inducing DNA damage | [21] |
| Low pathogenic oncolytic influenza virus IAV | IAV infection of Rb-fbx8 mice leads to reversal of immunosuppressed tumor-associated lung macrophage function to an M1-like pro-inflammatory active phenotype | [22] |
| Measles virus (MV) vaccine strains | MV oncolysis is associated with in vivo activation of caspase-3 | [23] |
| Oncolytic myxoma virus (MYXV) | Tumor-specific viral replication, induction of tumor necrosis, and growth inhibition-associated cytotoxic immune cell infiltration | [24] |
| Oncolytic adenovirus H101 | Very potent cytotoxicity, G2/M phase arrest, and cell lysis and inhibition of tumor growth | [25] |
| Oncolytic adenovirus Ad-apoptin | Ad-apoptin targets AMPK and inhibits glycolysis, migration, and invasion of lung cancer cells through the AMPK/mTOR signaling pathway | [26] |

### Table 2

| Registration Number | Title | Interventions | phase |
|---------------------|-------|---------------|-------|
| NCT02553229 | Mechanism of Action Trial of ColoAd1 (MDA) | Colo-Ad1 | Phase 1 |
| NCT05076760 | Study of M2M-BBB Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC) | M2M-BBB Immunomodulatory Injection | Phase 1 |
| NCT02879760 | Oncolytic MGL-MAGEA3 Vaccine With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients | Ad-MAGEA3, MGL-MAGEA3 | Phase 1/2 |
| NCT04723531 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | BT-001 | Phase 1/2 |
| NCT00861267 | Phase 2 Study of ICOLYSIN® in Combination With Fidaximab and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | | Phase 2 |
| NCT03004183 | IRBT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STORM) | ADV/SHV-10 | Phase 2 |
| NCT03740256 | Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA) | CABVEX | Phase 1 |
| NCT05150651 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-INF Injection in Relapsed/Refractory Solid Tumors | Recombinant L-INF adenovirus injection | Early phase 1 |
| NCT05205421 | A Study of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | Oncolytic Virus Injection (RT-01) | Phase 1 |
| NCT03401013 | Study of Tbo-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RACTOR) | Tbo-6517 | Phase 1/2 |
| NCT06425456 | Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors | Recombinant Vaccinia GM-CSF, RAC VAC GM-CSF (iK-594) | Phase 1 |
| NCT00314925 | Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | Seneca Valley Virus | Phase 1 |
| NCT01721018 | Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma. (1716-12) | HSV1716 Intra-pleural delivery | Phase 1/2 |
| NCT01503177 | Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma | oncolytic measles virus encoding thyroidal sodium iodide symporter | Phase 1 |

**Table 1**

Preclinical exploration on the specific mechanisms of OV in lung cancer treatment

**Reference**

[10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26].
potent antitumor immunity [61]. Oncolytic viruses expressing antibodies against immune checkpoint domains successfully combine the advantages of OV with an intratumoral expression of ICIs to enhance antitumor efficacy.

Apart from the combination with ICIs, the combination of OV with other therapies has gradually attracted people’s attention. The immunosuppressive tumor microenvironment (TME) is a huge obstacle to the success of adoptive cell therapy in solid tumors. Oncolytic immunotherapy with engineered adenovirus destroys the TME by infecting tumor cells as well as the surrounding stroma to improve tumor-directed chimeric antigen receptor (CAR)-T cell function [62]. Another study shows that FM21-NK cells could kill P/V virus-infected lung cancer cells more efficiently [63]. In terms of anti-angiogenic therapy, studies have used a herpes simplex virus 1 mutant (HSV-Endo) expressing endostatin in a mouse model of lung cancer. Tumor burden was significantly reduced in the orthotopic flank model, along with reduced microvessel density [64]. Measles attenuated Edmonston strain (MV-Edm) combined with NF-κB signaling pathway inhibitor pS1145 enhanced its oncolytic effect and promoted apoptosis in human lung cancer cells A549 and H1299 [65]. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-armed oncolytic adenovirus ZD55-TRAIL exhibits enhanced cytotoxicity and induces apoptosis in A549 spheres via the mitochondrial pathway, suggesting that the gene-armed oncolytic adenovirus is a potential therapeutic method for lung cancer [66]. Exploring the combination of standard treatment for lung cancer and OV is of increasing concern.

**Conclusion**

Until today, it becomes an irrefutable truth that we cannot eliminate all tumor cells as we can’t do that to coronavirus, how to live with them is the wisest choice. OV is one of the attractive modern experimental techniques for the treatment of human cancers, showing a remarkable antitumor effect on malignant tumors. But so far, only one OV has been approved by the FDA—T-Vec, a modified form of herpes simplex virus type 1 (HSV-1) [67]. Therefore, it deserves our unremitting efforts to continue to develop novel oncolytic viruses, deepen basic research on the specific mechanisms of immune modulation that enhance oncolytic virus replication and improve tumor-killing rates, and develop oncolytic combination therapies that can synergize with other existing standard treatments for lung cancer. More importantly, developing a vaccination system to prevent tumor progression and initiate long-term anti-tumor immune monitoring is of great significance for the treatment and prevention of lung cancer.

**Author contribution**

Dr. Zhang Li and Dr. Zhang Feiyue do equal contributions to the manuscript and are tied as the co-first author.

Dr. Haifeng Liang is the corresponding author of the manuscript.

Professor Li Gaofeng provided us with important advice and confidence in this revision, and our team unanimously agreed to include him as the second author of the article.

**Declaration of Competing Interest**

No conflict of interests exists in the submission of this manuscript, and the manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and is not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed.

**Table 3**

| Oncolytic virus       | Synergistic antitumor effect                                                                 | Ref       |
|-----------------------|---------------------------------------------------------------------------------------------|-----------|
| MYXV                  | Oncolytic myxoma virus (MYXV) combined with low-dose cisplatin enhances the treatment effect of lung cancer. | [24]      |
| P/V-CPI-5             | P/V-CPI-5 infection sensitizes airway cancer cells to DNA damaging agents, and combination with chemotherapeutic agents has enhanced the killing of airway cancer cells | [45]      |
| TG4010                | TG4010 in combination with standard chemotherapy in advanced NSCLC is feasible and well-tolerated. | [46]      |
|                       | TG4010 enhances chemotherapy efficacy in advanced NSCLC.                                      | [47]      |
|                       | TG4010 plus chemotherapy can improve progression-free survival.                                | [48]      |
| Pelareorep (reolysin) | Reolysin in combination with paclitaxel and carboplatin was well tolerated, and reovirus was beneficial to chemotherapy. | [49]      |
| Oncolytic Adenoviruses (OAds) | Oncolytic adenovirus combined with temozolomide synergistically enhances lung cancer cell death and significantly inhibits the growth of cyclophosphamide and GLV-1h68 have synergistic antitumor effects on PCI49PE-RFP lung adenocarcinoma xenografts | [50]      |
| GLV-1h68              |                                                                                               | [51]      |
| OBP-301 (Telomelysin) | the combination of OBP-301 and gemcitabine have therapeutic synergism in human lung tumor xenografts | [52]      |

**References**

1. Z. Li, Z. Feiyue, L. Gaofeng, Traditional Chinese medicine and lung cancer—From theory to practice, Biomed. Pharmacother. 157 (2021), 111381.
2. A. Nakao, et al., A Phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer, Cancer Gene Ther. 18 (3) (2011) 167–175.
3. N. Packirinawamy, et al., Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma, Leukemia 54 (12) (2020) 3310–3322.
4. P. Gao, G. Ding, L. Wang, The efficacy and safety of oncolytic viruses in the treatment of intermediate to advanced solid tumors: a systematic review and meta-analysis, Transl. Cancer Res. 10 (10) (2021) 4296–4302.
5. S. Thomas, et al., Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1, J. Immunother. Cancer 7 (1) (2019) 214.
6. A.S. Dach, M.R. Patel, Viroimmunotherapy of thoracic cancers, Biomedicines 5 (1) (2017).
7. R. Garcia-Carbonero, et al., Phase 1 study of intravenous administration of the chimeric adenovirus exadenotucvire in patients undergoing primary tumor resection, J. Immunother. Cancer 5 (1) (2017) 71.
8. Z. Zhang, et al., Treatment and prevention of lung cancer using a virus-infected reprogrammed somatic cell-derived tumor cell vaccination (ViReST) regime, Front. Immunol. 11 (2020) 19960.
9. A. Lahowal, R. Kumar, G.P.S. Raghava, In-silico identification of subunit vaccine candidates against lung cancer-associated oncogenic viruses, Comput. Biol. Med. 130 (2021), 104215.
10. K.S. Yurchenko, et al., Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model, PloS One 13 (4) (2018), e0195425.
11. T. Ye, et al., Oncolytic Newcastle disease virus induces autophagy-dependent immunogenic cell death in lung cancer cells, Am. J. Cancer Res. 8 (6) (2018) 1514–1527.
12. Z. Chai, et al., Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer, Virol. J. 11 (2014) 84.
13. L. Hu, et al., Oncolytic Newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy, Am. J. Cancer Res. 5 (12) (2015) 3612–3623.
14. B. Yaacov, et al., Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HU) in lung tumors, Cancer Gene Ther. 15 (12) (2008) 795–807.
15. H. Deng, et al., Coxackievirus type b3 is a potent oncolytic virus against KRAS-mutant lung adenocarcinoma, Mol. Ther. Oncolyt. 14 (2019) 266–278.
16. H. Liu, et al., MicroRNA modification of coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer, Mol. Ther. Oncolyt. 16 (2020) 207–218.
17. H. Liu, et al., Erratum: MicroRNA modification of coxsackievirus B3 decreases its toxicity, while retaining oncolytic potency against lung cancer, Mol Ther Oncolytics 20 (2021) 1–2.
18. M. Chodkowski, et al., First report of the oncolytic effect of EHV-1 on the non-small lung cancer - in vitro studies, Pol. J. Vet. Sci. 24 (4) (2021) 607–610.
19. J. Hu, et al., Tail armed oncolytic poxvirus suppresses lung cancer cell by inducing apoptosis, Acta Biochim. Biophys. Sin. (Shanghai) 50 (10) (2018) 1018–1027.
M.R. Patel, et al., Blood outgrowth endothelial cells as a cellular carrier for J.M. Li, et al., MicroRNA-145 regulates oncolytic herpes simplex virus-1 for advanced non-small-cell lung cancer: a controlled phase 2B trial, Lancet Oncol. 12 (12) (2011) 1125–1133.

J. de Sostoa, et al., Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.

C.A. Fajardo, et al., Oncolytic adenoviral delivery of an EGFR-targeting T-cell secreting a fibroblast activation protein-targeted bispecific T-cell engager, J. Immunother. Cancer 9 (4) (2021) 6852–6865.

J. Sostoa, et al., Targeting the tumor stroma with an oncolytic adenovirus secreting a fiberblast activation protein-targeted bispecific T-cell engager.

H. Khalique, et al., Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy, J. Immunother. Cancer 9 (4) (2021).

Z. Li et al. (2013) 241.

C.R. Fox, G.D. Parks, Histone deacetylase inhibitors enhance cell killing and block interferon-beta synthesis elicited by infection with an oncolytic parainfluenza virus, Viruses 11 (5) (2019).

R. Ramlau, et al., A phase II study of Tgs010 (Mva-MacI-IL2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer, J. Thorac. Oncol. 7 (7) (2008) 735–744.

E. Quoix, et al., Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial, Lancet Oncol. 12 (12) (2011) 1125–1133.

G. Song, et al., Ad-aeptin inhibits glycosylation, migration and invasion in lung cancer cells targeting AMPK/mTOR signaling pathway, Exp. Cell. Res. 409 (2) (2021), 112926.

M. Cook, A. Chaunden, Clinical application of oncolytic viruses: a systematic review, Int. J. Mol. Sci. 21 (20) (2020).

S. Ataseva, et al., Systemic cancer therapy with engineered adenovirus that evades innate immunity, Sci. Transl. Med. 12 (571) (2020).

B.K. Patel, et al., Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing interferon-β in preclinical models of non-small cell lung cancer, Transl. Oncol. 13 (7) (2020), 100762.

H. Oiao, et al., Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with Q1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy, Biomater. Sci. 8 (9) (2020) 2472–2490.

M. Garofalo, et al., Antitumor effect of oncolytic virus and paclitaxel encapsulated in extracellular vesicles for lung cancer treatment, J. Control. Rel. 283 (2018) 223–234.

S.H. Hong, et al., Aerosol gene delivery using viral vectors and cationic carriers for in vivo lung cancer therapy, Expert Opin. Drug Deliv. 12 (6) (2015) 977–991.

S.L. Wechman, et al., Development of an oncolytic adenovirus with enhanced spread ability through repeated UV irradiation and cancer selection, Viruses 8 (6) (2016).

D. Chen, et al., Combining IL-10 and oncolytic adenovirus demonstrates enhanced antitumor efficacy through CD8(+) T cells, Front. Immunol. 12 (2021), 615089.

S. Varghese, et al., Systemic oncolytic herpes virus therapy of poorly immunogenic human lung adenocarcinoma bearing mice, J. Transl. Med. 12 (2014) 197.

J.G. Gomez-Gutierrez, et al., Combined therapy of oncolytic adenovirus and temosolamide enhances lung cancer virotherapy in vitro and in vivo, Virology 487 (2016) 249–259.

E. Hofmann, S. Weibel, A.A. Szalay, Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice, J. Transl. Med. 12 (2014) 197.

D. Liu, et al., Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer, Mol. Cancer Ther. 8 (4) (2009) 980–987.

L. Zhang, et al., [CAR-T] immunotherapy and non-small cell lung cancer: bottleneck and dawn, Zhongguo Fei Ai Za Zhi 23 (10) (2020) 916–920.

V. Longo, et al., Strategies to improve cancer immune checkpoint inhibitors efficacy, other than abscopal effect: a systematic review, Cancers (Basel) 11 (4) (2019).

A. Ribas, et al., Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell 170 (6) (2017) 1109–1119, e10.

R. Parkarama, et al., Immune characterization of metastatic colorectal cancer patients post reovirus administration, BMC Cancer 20 (1) (2020) 569.

H. Jiang, et al., Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination, Cancer Res. 77 (14) (2017) 3894–3907.

D. Masemann, et al., Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers, Oncoimmunology 10 (1) (2021), 1885778.

F. Sun, et al., Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer, J. Immunother. Cancer 8 (1) (2020).

S. Zuo, et al., Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT), EBiomedicine 64 (2021), 103240.

S. Rambai, et al., Mesenchymal stem cell delivery of oncolytic virus, viral immune evasion and immune suppression against human lung and colorectal adenocarcinomas, Biomed. Res. Int. 2013 (2013), 387362.

P. Kellish, et al., Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival, J. Clin. Invest. 129 (6) (2019) 2279–2292.

H. Zhao, et al., Oncolytic adenovirus rAd.DCN inhibits breast tumor growth and lung metastasis in an immune-competent orthotopic xenograft model, Hum. Gene Ther. 30 (2) (2019) 197–210.

S. Chaurasiya, et al., A chimeric poxvirus with J2R (thymidine kinase) deletion elicits selective killing of human non-small cell lung cancer cells, Virol J 10 (2013) 241.

N. Boisgerault, et al., Natural oncolytic activity of live-attenuated measles virus in a mouse model of prostate cancer metastasis, J. Virol. 95 (3) (2021) 2520–2532.

M.K. McKenna, et al., Mesenchymal stromal cell delivery of oncolytic reovirus in combination with chemotherapy and radiotherapy improves anti-PD-1 immunotherapy, Cancer Metastasis Rev. 30 (2) (2019) 197–203.